Von Willebrand Disease News and Research

Latest Von Willebrand Disease News and Research

Hizentra therapy effective for primary immunodeficiency patients

Hizentra therapy effective for primary immunodeficiency patients

Octapharma USA launches wilate replacement therapy Web site for von Willebrand Disease

Octapharma USA launches wilate replacement therapy Web site for von Willebrand Disease

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Rush University Medical Center first to receive Octapharma grant under anniversary program

Rush University Medical Center first to receive Octapharma grant under anniversary program

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

CSL Behring granted authorization to market Berinert for HAE in Italy and Luxembourg

CSL Behring granted authorization to market Berinert for HAE in Italy and Luxembourg

U.S. healthcare practitioners can resume use of Rotarix, says FDA

U.S. healthcare practitioners can resume use of Rotarix, says FDA

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

CSL Behring donates life-saving medicines to assist earthquake victims in Haiti

CSL Behring donates life-saving medicines to assist earthquake victims in Haiti

Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting

Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting

Derma Sciences first-quarter net sales up 23% to $12,844,382

Derma Sciences first-quarter net sales up 23% to $12,844,382

CSL Behring calls for grant requests through LEAD program

CSL Behring calls for grant requests through LEAD program

FDA approves CSL Behring's Hizentra for PI

FDA approves CSL Behring's Hizentra for PI

Majority of PI patients can be switched to IgPro20 without dose adjustment

Majority of PI patients can be switched to IgPro20 without dose adjustment

C1-INH replacement therapy effective for treating acute swelling attacks in HAE

C1-INH replacement therapy effective for treating acute swelling attacks in HAE

Patients with HAE experience prodromal symptoms before acute HAE attacks: Survey

Patients with HAE experience prodromal symptoms before acute HAE attacks: Survey

IgPro20 protects PI patients against infection

IgPro20 protects PI patients against infection

FDA grants orphan drug exclusivity approval for Octapharma AG's wilate

FDA grants orphan drug exclusivity approval for Octapharma AG's wilate

Gene therapy may help correct molecular flaws that cause brain disease

Gene therapy may help correct molecular flaws that cause brain disease